Source Language English Spanish French Arabic Portuguese Russian Chinese Hindi Bengali Urdu Indonesian Swahili Hebrew German Japanese Turkish Persian Ukrainian Pashto Dari Somali 11:32 GMT ¶ uniQure Inc.: uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease Progression...Health